

Yaning Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8450599/publications.pdf>

Version: 2024-02-01

17
papers

191
citations

1307594

7
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

219
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. <i>Cancer Medicine</i> , 2023, 12, 335-344.	2.8	5
2	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2022, 12, 843299.	2.8	6
3	First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210823.	3.2	14
4	Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors. <i>Frontiers in Pharmacology</i> , 2022, 13, 806737.	3.5	3
5	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 187.	5.5	28
6	The expression of aryl hydrocarbon receptor predicts responses to anti-PD-1 antibodies in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2628-2628.	1.6	0
7	Assessment of ethnic difference in the incidence of thrombocytopenia induced by trastuzumab emtansine (T-DM1): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15096-e15096.	1.6	1
8	Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1139-1139.	1.7	4
9	EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 713483.	2.8	6
10	Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M cis-797S mutations in lung adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 8328-8337.	2.8	9
11	The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 63-69.	1.1	12
12	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. <i>Thoracic Cancer</i> , 2020, 11, 3501-3509.	1.9	9
13	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. <i>Lung Cancer</i> , 2020, 147, 229-236.	2.0	9
14	Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. <i>Targeted Oncology</i> , 2020, 15, 357-364.	3.6	9
15	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194.	2.0	68
16	Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. <i>Thoracic Cancer</i> , 2019, 10, 1096-1102.	1.9	1
17	Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9043-9043.	1.6	7